A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Intravenous Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects

Trial Profile

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Intravenous Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GMI-1271 in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs GMI 1271 (Primary)
  • Indications Acute myeloid leukaemia; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors GlycoMimetics
  • Most Recent Events

    • 08 Dec 2015 Results of this study and interim results of the study NCT02271113 (n = 18) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology.
    • 05 Dec 2015 Results from this and another phase I trial were presented at the 57th American Society of Hematology (ASH) Annual Meeting, according to a Glycomimetics media release.
    • 09 Nov 2015 Results will be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition, according to a GlycoMimetics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top